scholarly journals Guillain-Barre Syndrome Caused by Tislelizumab and Axitinib

2021 ◽  
Author(s):  
Yang Sun ◽  
Yanjun Guo ◽  
Yaqing Wu ◽  
Ningning Luo ◽  
Xinjia He
Keyword(s):  
Renal Cell Carcinoma ◽  
Nervous System ◽  
T Cell ◽  
Adverse Events ◽  
Renal Cell ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Treatment Paradigm ◽  
Triggering Factor ◽  
Guillain Barré

Abstract Immunotherapy combinations have changed the treatment paradigm of advanced renal cell carcinoma (RCC). Notably, immunotherapy induces a new spectrum of immune-related adverse events (irAEs). Guillain–Barré syndrome (GBS) is a rare and potentially fatal nervous system irAE. The activation of T-cell is considered a triggering factor of GBS. We herein reported a case of GBS-like syndrome during treatment of tislelizumab and axitinib in a patient with RCC. To our knowledge, this is the first report of tislelizumab-related GBS.

Guillain–Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy

2017 ◽  
Vol 23 (11) ◽  
pp. 798-799 ◽  
Author(s):  
Hiroaki Koshikawa ◽  
Tomomi Tsukie ◽  
Akira Kurita ◽  
Mikio Fujikura ◽  
Megumi Suzuki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barré Syndrome following Treatment with Sunitinib Malate

2014 ◽  
Vol 2014 ◽  
pp. 1-2 ◽  
Author(s):  
Ziad Kanaan ◽  
Zain Kulairi ◽  
Mirela Titianu ◽  
Sandip Saha ◽  
Sarwan Kumar
Keyword(s):  
Renal Cell Carcinoma ◽  
Side Effects ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Guillain Barre Syndrome ◽  
Sunitinib Malate ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib’s inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different neuropathies. We hereby report an interesting case of Guillain-Barré syndrome in a middle-aged patient with metastatic renal cell carcinoma following sunitinib treatment.

scholarly journals Guillain-Barre syndrome: a typical paraneoplastic syndrome in a kidney transplant recipient with allograft renal cell carcinoma: a case report and review of the literature

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Izabela Zakrocka ◽  
Iwona Baranowicz-Gąszczyk ◽  
Agnieszka Korolczuk ◽  
Wojciech Załuska
Keyword(s):  
Renal Cell Carcinoma ◽  
Kidney Transplantation ◽  
Cell Carcinoma ◽  
Kidney Transplant ◽  
Renal Cell ◽  
Guillain Barre Syndrome ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Abstract Background Guillain-Barré syndrome (GBS) is an autoimmune polyneuropathy affecting the peripheral nervous system. This neurological disorder has been previously reported in bone marrow transplant recipients but is uncommon after kidney transplantation. Viral infections and calcineurin inhibitors are the main triggers of GBS in renal transplant recipients. Case presentation In this report, we present a case of a 47-year-old male patient 12 years after his second kidney transplantation who developed GBS due to papillary renal cell carcinoma. Infectious and drug-related origins of GBS were excluded. Despite intensive treatment, graftectomy was performed, after which neurological symptoms resolved. Conclusions In kidney transplant recipients, paraneoplastic aetiology should be considered in the differential diagnosis of GBS.

scholarly journals Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab

2019 ◽  
Vol 12 (8) ◽  
pp. e230848 ◽  
Author(s):  
Julien Pierrard ◽  
Bénédicte Petit ◽  
Sarah Lejeune ◽  
Emmanuel Seront
Keyword(s):  
Adverse Events ◽  
Adrenocorticotropic Hormone ◽  
Checkpoint Inhibitors ◽  
Left Kidney ◽  
Neurological Complication ◽  
Guillain Barre Syndrome ◽  
Hormone Deficiency ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Lumbar Spinal

The increased use of immune checkpoint inhibitors (ICIs) has led to the observation of a variety of immune-related adverse events (irAEs). These irAEs occur usually within the first months after ICIs onset and can involve theorically all organs. We describe two rare irAEs occurring in a 70-year-old caucasian man who was treated with nivolumab for an advanced urothelial cancer of the left kidney. He developed an isolated adrenocorticotropic hormone deficiency that was diagnosed at week 19 and a neurological complication that appeared at week 79 and initially confounded with a lumbar spinal stenosis. Diagnosis of Guillain-Barré syndrome was finally confirmed with the complete resolution of symptoms after 5 days of intravenous immunoglobulin and corticosteroids. We highlight the importance of quickly recognising these potential life-threatening irAEs such as cortisol insufficiency and neurologic adverse events whose initially presentation could be non-specific.

Sign in / Sign up

Export Citation Format

Share Document